Entrada Therapeutics, Inc. (TRDA) Stock

Entrada Therapeutics, Inc. (TRDA) is a Healthcare stock trading at $7.59 (as of 2026-08-21), with a market capitalization of $294.65M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Understand Entrada Therapeutics, Inc.: how it makes money

Entrada Therapeutics develops endosomal escape vehicle (EEV) therapeutics for multiple neuromuscular diseases, advancing programs like ENTR-601-44, and it makes money from collaboration revenue.

Its near term revenue base appears to come from collaboration revenue, while the longer term path to profitability depends on advancing its EEV platform programs such as ENTR-601-44, where the operating readouts include exon skipping responses in study cohorts.

Revenue by segment (latest quarter)
Collaboration Revenue	$0.0B

Business quality (Weak): Segment breakdown is limited to one disclosed revenue line (collaboration revenue). Operating KPIs provided are mostly development readouts from program studies, and the latest quarter shows very large operating losses (operating margin -4834.6%).

Bull case

EEV platform with multiple therapeutic program types: The company’s endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs for multiple neuromuscular diseases.
Preclinical lead program has measurable exon skipping readouts: ENTR-601-44 includes a 6 mg/kg cohort readout with mean exon skipping of 0.44% and statistical significance versus placebo with a p-value of 0.01.
Some collaboration revenue is already present: The latest quarter includes Collaboration Revenue of 0.02B, indicating active collaboration funding or monetization.

Bear case

Stage of development and uncertainty: ENTR-601-44 is described as preclinical, and EEV-PMO-CAG is also tied to myotonic dystrophy type 1 development, which leaves significant execution risk before commercialization.
Ongoing heavy losses: The latest period shows operating margin of -4834.6%, consistent with substantial operating losses.
Revenue is small and appears concentrated in collaborations: Only Collaboration Revenue is provided in the segment candidates (0.02B), so near term revenue visibility may be limited.

Valuation — source: SEC EDGAR (first-party)
Price	$7.59
Market Cap	$294.65M
Price / Book	1.09
Price / Sales	11.79
FCF Yield	-84.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$25.42M
Net Margin	-565.5%
Revenue Growth (YoY)	-87.9%
EPS Growth (YoY)	-297.2%
FCF Growth (YoY)	189.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.02 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($64.02M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dipal Doshi
Employees	183
Country	US
IPO Date	2021-10-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.